Detail akcie Jazz Pharma online

Business Summary: Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Financial Summary: BRIEF: For the nine months ended 30 September 2020, JazzPharmaceuticals PLC revenues increased 7% to $1.7B. Netincome decreased 77% to $105.2M. Revenues reflect Xyremsegment increase of 8% to $1.3B, Sunosi segment increasefrom $987K to $19.6M, United States segment increase of 7%to $1.54B, Europe segment increase of 17% to $125.2M. Netincome was offset by Acquired in-process research anddevelop increase of 96% to $215.3M (expense), Selling.